Miguel Varela
Senior Postdoctoral Scientist / Team Leader
My main focus is on pre-clinical translational research. I am especially interested in degenerative disorders of the nervous system and muscle.
In my current role, I am lead scientist in a number of public-funded projects and collaborative programs with pharmaceutical companies, where we explore the efficacy of novel therapeutic targets, and facilitate the in vivo delivery of oligonucleotides and RNA-based therapeutics to improve the biodistribution these drugs.
Recent publications
-
Preclinical characterization of antagomiR-218 as a potential treatment for myotonic dystrophy.
Journal article
Cerro-Herreros E. et al, (2021), Mol Ther Nucleic Acids, 26, 174 - 191
-
Comparable Outcomes of Matched Sibling Donor and Matched Unrelated Donor Stem Cell Transplantation in Children With Acute Leukemia in Argentina.
Journal article
Gómez SM. et al, (2021), J Pediatr Hematol Oncol
-
Application of CRISPR-Cas9-Mediated Genome Editing for the Treatment of Myotonic Dystrophy Type 1.
Journal article
Marsh S. et al, (2020), Mol Ther, 28, 2527 - 2539
-
A Single Amino Acid Residue Regulates PTEN-Binding and Stability of the Spinal Muscular Atrophy Protein SMN.
Journal article
Rademacher S. et al, (2020), Cells, 9
-
Development of LNA Gapmer Oligonucleotide-Based Therapy for ALS/FTD Caused by the C9orf72 Repeat Expansion.
Journal article
Sathyaprakash C. et al, (2020), Methods Mol Biol, 2176, 185 - 208